Remicade biosimilars launched
Enlarge image


Remicade biosimilars launched

26.02.2015 - It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

It was a good run for Janssen Biotech and its Antirheumatic biologic Remicade (infliximab). The blockbuster drug has yielded record sales, netting the company and its commercialisation partner Merck & Co billions of dollar in sales. But now, the companies are in for some stormy weather: just hours after the patent of the drug expired, the first biosimilars were launched on European Markets.

Mundipharma International Ltd is launching Remsima this month in Germany, Italy, UK and Benelux. The British company had secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. Meanwhile, rival Hospira, newly acquired by Pfizer, is launching its own version of the biosimilar, Inflectra, in the UK, Germany and Italy as well as France, Austria, Denmark, Greece, Luxembourg, the Netherlands, Spain, and Sweden. Hospira and Celltrion have a long-standing partnership that allows both to market the infliximab biosimilar under their own brands.

Infliximab biosimilar is the first biosimilar monoclonal antibody approved by the European Medicines Agency (EMA). It is authorised to treat the same conditions as its reference product Remicade: rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis. It remains to be seem how big a chunk the copycat products can take from Remicade’s earnings.

From the magazine: Will mAb biosimilars end the dry spell?



23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).


19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.


17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.


12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.


10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.


04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

© 2007-2015 BIOCOM


All Events



1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%
  • ADDEX3.20 CHF0.00%


  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%


  • WILEX3.43 EUR75.0%
  • BASILEA122.20 CHF16.3%
  • ACTELION114.40 CHF13.5%


  • SANTHERA94.55 CHF-10.0%
  • 4SC0.78 EUR-7.1%


  • SANTHERA94.55 CHF2330.6%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%


  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 28.02.2015